Literature DB >> 7649350

The expression of prostatic acid phosphatase is transcriptionally regulated in human prostate carcinoma cells.

R Garcia-Arenas1, F F Lin, D Lin, L P Jin, C C Shih, C Chang, M F Lin.   

Abstract

The expression of prostatic acid phosphatase (PAcP) in three human prostate carcinoma cell lines including LNCaP, DU 145 and PC-3, was studied to explore its potential role as a marker in the progression of prostate cancer. Although Southern blot analysis suggested the presence of PAcP gene in all three prostate carcinoma cell lines, the Northern blot analysis and the reverse transcriptase-polymerase chain reaction (RT-PCR) assay showed that PAcP mRNA can be detected only in LNCaP cells. As one of the major differences between LNCaP cells and PC-3 as well as DU 145 cells is the androgen-sensitivity of LNCaP cells, we then focused on the influence of PAcP expression by the presence of androgen receptor (AR) in human AR cDNA-transfected PC-3 cells and high passages of LNCaP cells. The results demonstrated that the transfection of human AR cDNA into PC-3 cells did not have any detectable effect on the expression of PAcP. Further, in LNCaP cells, while the level of PAcP mRNA diminished upon passage, the AR mRNA level remained approximately the same. Together, these data suggested that the differential expression of PAcP in different prostate carcinoma cells including high passages of LNCaP cells may occur at the transcriptional level and may have little linkage to the expression of AR.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7649350     DOI: 10.1016/0303-7207(95)03544-h

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  6 in total

1.  Expression of receptor protein tyrosine phosphatase alpha mRNA in human prostate cancer cell lines.

Authors:  S Zelivianski; J Dean; D Madhavan; F F Lin; M F Lin
Journal:  Mol Cell Biochem       Date:  2000-05       Impact factor: 3.396

2.  Monoclonal anti-androgen receptor antibodies: production, characterization and potential diagnostic applications.

Authors:  C C Shih; W J Young; C H Wang; L P Jin; X D Ji; Q Guan; M Wang; C Chang
Journal:  Mol Cell Biochem       Date:  1999-11       Impact factor: 3.396

3.  Histone deacetylase inhibitor valproic acid suppresses the growth and increases the androgen responsiveness of prostate cancer cells.

Authors:  Yu-Wei Chou; Nagendra K Chaturvedi; Shougiang Ouyang; Fen-Fen Lin; Dharam Kaushik; Jue Wang; Isaac Kim; Ming-Fong Lin
Journal:  Cancer Lett       Date:  2011-07-22       Impact factor: 8.679

4.  Cell-cell interaction in prostate gene regulation and cytodifferentiation.

Authors:  A Y Liu; L D True; L LaTray; P S Nelson; W J Ellis; R L Vessella; P H Lange; L Hood; G van den Engh
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-30       Impact factor: 11.205

5.  TBLR1 as an androgen receptor (AR) coactivator selectively activates AR target genes to inhibit prostate cancer growth.

Authors:  Garrett Daniels; Yirong Li; Lan Lin Gellert; Albert Zhou; Jonathan Melamed; Xinyu Wu; Xinming Zhang; David Zhang; Daniel Meruelo; Susan K Logan; Ross Basch; Peng Lee
Journal:  Endocr Relat Cancer       Date:  2014-01-16       Impact factor: 5.678

Review 6.  Supraphysiologic Testosterone Therapy in the Treatment of Prostate Cancer: Models, Mechanisms and Questions.

Authors:  Osama S Mohammad; Michael D Nyquist; Michael T Schweizer; Stephen P Balk; Eva Corey; Stephen Plymate; Peter S Nelson; Elahe A Mostaghel
Journal:  Cancers (Basel)       Date:  2017-12-06       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.